Abstract-based review · 2019
Specific egg antibodies and active Fel d1 in cat saliva
Immunoactive salivary Fel d1 decreased; 82% of treated cats had at least a 20% reduction versus 38% of controls.
Review scope
Abstract-based review. Full methods, complete statistical results and product equivalence have not been appraised. This is research context, not an individual feeding or treatment recommendation.
Study question and design
Cats in two feeding experiments. Diets containing a specific anti-Fel d1 immunoglobulin Y egg ingredient, with baseline periods and one controlled trial.
Main findings
Immunoactive salivary Fel d1 decreased; 82% of treated cats had at least a 20% reduction versus 38% of controls.
Limitations and applicability
Ordinary egg ingredients are not equivalent to the tested antibody preparation. This study did not test symptoms in people with cat allergies.
Ingredients investigated
Direct ingredient investigations
Egg
Direct · cat. Cats in two feeding experiments assessing active salivary Fel d 1.
Tested form: Egg ingredient containing anti-Fel d 1 immunoglobulin Y antibodies. Dose: Not reported in reviewed abstract (Oral feeding; exact dose basis not reported in reviewed abstract). Duration: One-week baseline followed by four weeks of treatment. Comparator: Control food in the controlled feeding experiment.
Measured finding: In the controlled experiment, 82% of treated cats had at least a 20% reduction in active salivary Fel d 1, compared with 38% of control cats. This controlled result should not be assigned to the pilot trial as an independent estimate.
Limitations: Specific egg-antibody ingredient; human clinical allergy outcomes were not measured. Dose and sample details are not established in the reviewed abstract.
Egg
Direct · cat. Cats in two feeding experiments assessing active salivary Fel d 1.
Tested form: Egg ingredient containing anti-Fel d 1 immunoglobulin Y antibodies. Dose: Not reported in reviewed abstract (Oral feeding; exact dose basis not reported in reviewed abstract). Duration: Two-week baseline followed by six weeks of treatment. Comparator: Baseline feeding before the egg-antibody ingredient.
Measured finding: In the controlled experiment, 82% of treated cats had at least a 20% reduction in active salivary Fel d 1, compared with 38% of control cats. This controlled result should not be assigned to the pilot trial as an independent estimate.
Limitations: Specific egg-antibody ingredient; human clinical allergy outcomes were not measured. Dose and sample details are not established in the reviewed abstract.
Evidence.pet interpretation
Apply this result only within its species, preparation and study conditions. An ingredient listing alone does not establish that a commercial product reproduces the tested intervention.
Funding and conflicts
Not established from the reviewed abstract.
Ingredient references
Egg.
These are research references. The tested form, dose and formulation must be matched before using a result to support a product claim.
Source
Satyaraj E; Li Q; Sun P; Sherrill S. Anti-Fel d1 immunoglobulin Y antibody-containing egg ingredient lowers allergen levels in cat saliva. Journal of Feline Medicine and Surgery. 2019. DOI: 10.1177/1098612X19861218.
Primary source record (PMID 31310154) · Publisher DOI
Reviewed 2 October 2026 · Next review 2 January 2027.